SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates
NC Kyriakidis, A López-Cortés, EV González… - npj Vaccines, 2021 - nature.com
The new SARS-CoV-2 virus is an RNA virus that belongs to the Coronaviridae family and
causes COVID-19 disease. The newly sequenced virus appears to originate in China and …
causes COVID-19 disease. The newly sequenced virus appears to originate in China and …
COVID-19 transmission, current treatment, and future therapeutic strategies
VS Salian, JA Wright, PT Vedell, S Nair… - Molecular …, 2021 - ACS Publications
At the stroke of the New Year 2020, COVID-19, a zoonotic disease that would turn into a
global pandemic, was identified in the Chinese city of Wuhan. Although unique in its …
global pandemic, was identified in the Chinese city of Wuhan. Although unique in its …
[HTML][HTML] Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B. 1.1. 7): an exploratory analysis of a randomised …
Background A new variant of SARS-CoV-2, B. 1.1. 7, emerged as the dominant cause of
COVID-19 disease in the UK from November, 2020. We report a post-hoc analysis of the …
COVID-19 disease in the UK from November, 2020. We report a post-hoc analysis of the …
[HTML][HTML] T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of
Coronavirus Disease 2019 (COVID-19), has caused a global pandemic, and safe, effective …
Coronavirus Disease 2019 (COVID-19), has caused a global pandemic, and safe, effective …
Immunological considerations for COVID-19 vaccine strategies
Abstract The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) is the most formidable challenge to …
respiratory syndrome coronavirus 2 (SARS-CoV-2) is the most formidable challenge to …
Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: interim analysis of 2 randomized clinical trials
S Xia, K Duan, Y Zhang, D Zhao, H Zhang, Z Xie, X Li… - Jama, 2020 - jamanetwork.com
Importance A vaccine against coronavirus disease 2019 (COVID-19) is urgently needed.
Objective To evaluate the safety and immunogenicity of an investigational inactivated whole …
Objective To evaluate the safety and immunogenicity of an investigational inactivated whole …
[HTML][HTML] Antigen-specific adaptive immunity to SARS-CoV-2 in acute COVID-19 and associations with age and disease severity
Limited knowledge is available on the relationship between antigen-specific immune
responses and COVID-19 disease severity. We completed a combined examination of all …
responses and COVID-19 disease severity. We completed a combined examination of all …
COVID-19 vaccine frontrunners and their nanotechnology design
YH Chung, V Beiss, SN Fiering, NF Steinmetz - ACS nano, 2020 - ACS Publications
Humanity is experiencing a catastrophic pandemic. SARS-CoV-2 has spread globally to
cause significant morbidity and mortality, and there still remain unknowns about the biology …
cause significant morbidity and mortality, and there still remain unknowns about the biology …
Antibody response to SARS-CoV-2 infection in humans: A systematic review
N Post, D Eddy, C Huntley, MCI Van Schalkwyk… - PloS one, 2020 - journals.plos.org
Background Progress in characterising the humoral immune response to Severe Acute
Respiratory Syndrome 2 (SARS-CoV-2) has been rapid but areas of uncertainty persist …
Respiratory Syndrome 2 (SARS-CoV-2) has been rapid but areas of uncertainty persist …
[HTML][HTML] Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults
MJ Mulligan, KE Lyke, N Kitchin, J Absalon, A Gurtman… - Nature, 2020 - nature.com
Abstract In March 2020, the World Health Organization (WHO) declared coronavirus disease
2019 (COVID-19), which is caused by severe acute respiratory syndrome coronavirus 2 …
2019 (COVID-19), which is caused by severe acute respiratory syndrome coronavirus 2 …